Related Stories
A Challenge to Gene Theory, a Tougher Look at Biotech
Key Excerpts from Article on Website of New York Times
Posted: August 9th, 2007
http://www.nytimes.com/2007/07/01/business/yourmoney/01frame...
The $73.5 billion global biotech business may soon have to grapple with a discovery that calls into question the scientific principles on which it was founded. Last month, a consortium of scientists published findings that challenge the traditional view of how genes function. The exhaustive four-year effort was organized by the U.S. National Human Genome Research Institute and carried out by 35 groups from 80 organizations around the world. To their surprise, researchers found that the human genome might not be a tidy collection of independent genes after all, with each sequence of DNA linked to a single function, such as a predisposition to diabetes or heart disease. Instead, genes appear to operate in a complex network, and interact and overlap with one another and with other components in ways not yet fully understood. According to the institute, these findings will challenge scientists to rethink some long-held views about what genes are and what they do. Biologists have recorded these network effects for many years in other organisms. But in the world of science, discoveries often do not become part of mainstream thought until they are linked to humans. With that link now in place, the report is likely to have repercussions far beyond the laboratory. The presumption that genes operate independently has been institutionalized since 1976, when the first biotech company was founded. In fact, it is the economic and regulatory foundation on which the entire biotechnology industry is built. The principle that gave rise to the biotech industry promised benefits that were equally compelling. Known as the Central Dogma of molecular biology, it stated that each gene in living organisms, from humans to bacteria, carries the information needed to construct one protein.